T. Rowe Price Associates’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $347K | Buy |
249,155
+36,475
| +17% | +$50.1K | ﹤0.01% | 2615 |
|
|
2025
Q4 | $343K | Buy |
212,680
+9,511
| +5% | +$19.9K | ﹤0.01% | 2576 |
|
|
2025
Q3 | $555K | Buy |
203,169
+19,905
| +11% | +$66.2K | ﹤0.01% | 2322 |
|
|
2025
Q2 | $668K | Buy |
183,264
+29,894
| +19% | +$82.1K | ﹤0.01% | 2163 |
|
|
2025
Q1 | $295K | Buy |
153,370
+15,465
| +11% | +$31.6K | ﹤0.01% | 2477 |
|
|
2024
Q4 | $263K | Buy |
137,905
+11,257
| +9% | +$19.5K | ﹤0.01% | 2565 |
|
|
2024
Q3 | $168K | Hold |
126,648
| – | – | ﹤0.01% | 2708 |
|
|
2024
Q2 | $130K | Buy |
126,648
+66,748
| +111% | +$82.5K | ﹤0.01% | 2705 |
|
|
2024
Q1 | $110K | Hold |
59,900
| – | – | ﹤0.01% | 2762 |
|
|
2023
Q4 | $75K | Hold |
59,900
| – | – | ﹤0.01% | 2757 |
|
|
2023
Q3 | $69K | Sell |
59,900
-22,900
| -28% | -$29.4K | ﹤0.01% | 2729 |
|
|
2023
Q2 | $76K | Sell |
82,800
-22,700
| -22% | -$21.9K | ﹤0.01% | 2739 |
|
|
2023
Q1 | $60K | Sell |
105,500
-61,400
| -37% | -$46.9K | ﹤0.01% | 2766 |
|
|
2022
Q4 | $96K | Hold |
166,900
| – | – | ﹤0.01% | 2724 |
|
|
2022
Q3 | $54K | Buy |
166,900
+119,800
| +254% | +$47K | ﹤0.01% | 2826 |
|
|
2022
Q2 | $17K | Sell |
47,100
-15,507
| -25% | -$6.51K | ﹤0.01% | 2936 |
|
|
2022
Q1 | $45K | Buy |
62,607
+18,149
| +41% | +$38.8K | ﹤0.01% | 2931 |
|
|
2021
Q4 | $100K | Sell |
44,458
-3,100
| -7% | -$8.45K | ﹤0.01% | 2872 |
|
|
2021
Q3 | $137K | Buy |
47,558
+1,535
| +3% | +$4.38K | ﹤0.01% | 2790 |
|
|
2021
Q2 | $174K | Buy |
46,023
+3,349
| +8% | +$11.3K | ﹤0.01% | 2758 |
|
|
2021
Q1 | $144K | Sell |
42,674
-69
| -0.2% | -$249 | ﹤0.01% | 2749 |
|
|
2020
Q4 | $120K | Buy |
42,743
+6,146
| +17% | +$17.9K | ﹤0.01% | 2615 |
|
|
2020
Q3 | $92K | Buy |
36,597
+9,000
| +33% | +$79K | ﹤0.01% | 2516 |
|
|
2020
Q2 | $375K | Buy |
27,597
+1,205
| +5% | +$12.5K | ﹤0.01% | 2171 |
|
|
2020
Q1 | $200K | Buy |
26,392
+740
| +3% | +$5.76K | ﹤0.01% | 2317 |
|
|
2019
Q4 | $162K | Buy |
25,652
+4,578
| +22% | +$21.8K | ﹤0.01% | 2425 |
|
|
2019
Q3 | $83K | Buy |
21,074
+651
| +3% | +$2.79K | ﹤0.01% | 2467 |
|
|
2019
Q2 | $99K | Buy |
20,423
+846
| +4% | +$4.81K | ﹤0.01% | 2478 |
|
|
2019
Q1 | $160K | Buy |
19,577
+200
| +1% | +$1.37K | ﹤0.01% | 2430 |
|
|
2018
Q4 | $107K | Sell |
19,377
-3,213
| -14% | -$25.1K | ﹤0.01% | 2482 |
|
|
2018
Q3 | $199K | Buy |
22,590
+297
| +1% | +$2.66K | ﹤0.01% | 2461 |
|
|
2018
Q2 | $222K | Buy |
22,293
+107
| +0.5% | +$1.07K | ﹤0.01% | 2428 |
|
|
2018
Q1 | $211K | Buy |
+22,186
| New | +$310K | ﹤0.01% | 2399 |
|
Other funds holding AKBA
VCM
VPM
T. Rowe Price Associates's AKBA Position: Q1 2026 in Review
T. Rowe Price Associates increased its Akebia Therapeutics (AKBA) stake by 17% in Q1 2026, buying an estimated $50.1K and bringing the position to 249,155 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #2615.
T. Rowe Price Associates first reported a position in AKBA in Q1 2018 and has held it in 33 quarters since. The position peaked at $668K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- T. Rowe Price Associates held 249,155 shares of Akebia Therapeutics worth $347K as of Q1 2026.
- T. Rowe Price Associates bought 36,475 Akebia Therapeutics shares in Q1 2026, an estimated $50.1K.
- Akebia Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2615 holding.
- T. Rowe Price Associates first reported a position in Akebia Therapeutics in Q1 2018 and has held it in 33 quarters since.
- T. Rowe Price Associates's Akebia Therapeutics position peaked at $668K in Q2 2025.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.